Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract Background The Washington University Memory Diagnostic Center (MDC) in St. Louis, Missouri, annually sees approximately 4,000 patients with memory and thinking concerns and uses multiple biomarker modalities to assess for AD pathology, including to establish eligibility for anti‐amyloid treatments. We assessed the use of different biomarker modalities over time and the rates of biomarker positivity by sex and racial group. Method Biomarker positivity was based on the clinical interpretation of the Elecsys p ‐tau181/Aβ42 CSF test (Roche), the PrecivityAD and PrecivityAD2 blood tests (C2N Diagnostics), and Florbetaben or Florbetapir amyloid PET scans. Clinical and demographic data were retrospectively collected from electronic health records. Result A total of 970 patients were included who underwent at least one AD biomarker test between June 2021 and December 2024 at the MDC and/or anti‐amyloid treatment initiation. The average patient age was 71.5 ± 9.3 years (mean ± standard deviation), 51% were female, and 93% were White. The numbers of tests performed were as follows: 500 CSF tests, 290 amyloid PET scans, 143 PrecivityAD2 blood tests, and 87 PrecivityAD blood tests (Table 1). 50 patients underwent testing with more than one biomarker modality. The monthly volume of biomarker testing increased from ∼10 patients/month from July 2021‐July 2022 to ∼40 patients/month from July 2023‐July 2024 (Figure 1). Females were more likely than males to be biomarker positive: for CSF tests, 73% females and 65% males were positive, p = 0.041; for amyloid PET, 77% females and 67% males were positive, p = 0.045; for the PrecivityAD2 blood test, 82% females and 63% males were positive, p = 0.010 (Figure 2a). Only 42 individuals undergoing biomarker testing were Black (4%). White individuals were more likely than Black individuals to be biomarker positive on CSF tests (71% White and 35% Black were positive, p = 0.0018); few Black individuals underwent amyloid PET or blood tests (Figure 2b). Conclusion The MDC used a combination of CSF tests, blood tests, and amyloid PET scans to scale up AD biomarker testing over the past three years. Rates of AD biomarker positivity were approximately 70% across all three modalities, with females and White individuals having higher rates of positivity.

What this study adds

Evidence grade: Low

The record lists 4,000 participants. This study describes how a specialty memory clinic used different Alzheimer's disease biomarker tests over time and the rates of biomarker positivity by sex and racial group, based on 970 patients tested between June 2021 and December 2024. It is a description of testing patterns in one clinic and does not test any treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hofmann, A., Paczynski, M., Posey, Z. J., Aldinger, M., Benzinger, T. L., Morris, J. C., et al. (2025). Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105627

Vancouver

Hofmann A, Paczynski M, Posey ZJ, Aldinger M, Benzinger TL, Morris JC, et al. Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105627.

BibTeX

@article{hofmann2025-d8ce6554,
  author  = {Hofmann, Anna and Paczynski, Madeline and Posey, Zachary J and Aldinger, Melissa and Benzinger, Tammie L.S. and Morris, John C. and Snider, B. Joy and Schindler, Suzanne Elizabeth},
  title   = {{Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_105627},
  url     = {https://doi.org/10.1002/alz70856_105627}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study describes how a specialty memory clinic used different Alzheimer's disease biomarker tests over time and the rates of biomarker positivity by sex and racial group, based on 970 patients tested between June 2021 and December 2024. It is a description of testing patterns in one clinic and does not test any treatment, cure or prevention.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 4,000 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Suzanne Elizabeth Schindler: h-index 56 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also in Treatments

187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →